BPH and PTCA on first agenda for IQWIG - Germany's HTA institute
This article was originally published in Clinica
The first work programme of IQWIG, the German institute for healthcare product quality and cost-effectiveness, includes four device technologies/procedures and an evaluation of a fast-acting insulin analogue.
You may also be interested in...
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.